Evidence map›Paper›PMID 31646374›Full record

ArticleJournal of cancer research and clinical oncology2019

Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer.

Ying Wang, Yanxia Liu, Lina Zhang, Li Tong, Yuan Gao, Fanbin Hu, Peter Ping Lin, Baolan Li, Tongmei Zhang

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Circulating Tumor Cells for the Monitoring of Lung Cancer Therapies.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Ying WangDepartment of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.
Yanxia LiuDepartment of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.
Lina ZhangDepartment of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.
Li TongDepartment of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.
Yuan GaoDepartment of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.
Fanbin HuDepartment of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.
Peter Ping LinCytelligen, San Diego, CA, USA.
Baolan LiDepartment of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China. libaolan1109@163.com.
Tongmei ZhangDepartment of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China. tongmeibj@163.com.ORCID http://orcid.org/0000-0003-4271-3773
Capital Medical University · CNCytel (United States) · US

Funding

Beijing Municipal Science & Technology Commission 171100001017038Beijing universities advanced subject construction project the joint project of capital medical university and Peking union medical college on clinical medicine 11920703Tongzhou district science and technology committee project KJ2019CX015Tongzhou lianggao talents project YH201920
6 · The paper itself

Abstract

objectiveTo investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer.

methodsPeripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy.

resultsBefore treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (≤ 5 µm of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vim

conclusionsThis study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim

Indexed as

Chromosomes, Human, Pair 8FemaleFollow-Up StudiesHumansLiver NeoplasmsLung NeoplasmsMaleMiddle AgedNeoplastic Cells, CirculatingProgression-Free SurvivalProspective StudiesVimentinVimentinAdvanced lung cancerAneuploidy of Chr8Cell sizeCirculating tumor cellsProgression-free survivalVimentin

Identifiers

PMID31646374
PMCPMC6861204
OpenAlexW2982096748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.